Abstract
Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac.
Daniel E Furst, Karen S Kolba, Roy Fleischmann, Joel Silverfield, Maria Greenwald, Sanford Roth, David B Hall, Paul J Roszko and Meloxicam Rheumatoid Arthritis Investigators
The Journal of Rheumatology March 2002, 29 (3) 436-446;
Daniel E Furst
Karen S Kolba
Roy Fleischmann
Joel Silverfield
Maria Greenwald
Sanford Roth
David B Hall
In this issue
Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac.
Daniel E Furst, Karen S Kolba, Roy Fleischmann, Joel Silverfield, Maria Greenwald, Sanford Roth, David B Hall, Paul J Roszko, Meloxicam Rheumatoid Arthritis Investigators
The Journal of Rheumatology Mar 2002, 29 (3) 436-446;
Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac.
Daniel E Furst, Karen S Kolba, Roy Fleischmann, Joel Silverfield, Maria Greenwald, Sanford Roth, David B Hall, Paul J Roszko, Meloxicam Rheumatoid Arthritis Investigators
The Journal of Rheumatology Mar 2002, 29 (3) 436-446;